Autonomous diabetic retinopathy screening from retinal imaging.
First FDA-authorized fully autonomous AI diagnostic system across any medical specialty.
Vendor press release citing growth and named primary-care deployment (OSF HealthCare).
Named deployment site (OSF HealthCare) is real and identifiable, though the growth figures cited are vendor-reported.
Documented primary-care deployment (e.g. OSF HealthCare); vendor claims rapid growth without an independently audited total.
As a fully autonomous diagnostic tool, the clinical accountability model (no physician second read) must be explained clearly on the public profile.
This profile is not medical advice or an endorsement. Hospitals should perform their own due diligence (regulatory compliance, GDPR, cybersecurity, integration, local clinical validation). How we evaluate
Every profile documents the precise indication, regulatory status, vendor-supported and independent evidence, real-world deployment, limits and dated sources.
A independent systematic review or prospective multicentre study · B at least one independent peer-reviewed study · C peer-reviewed, vendor-supported · D vendor claims only.
Vendors, authors and clinicians can request a correction. Corrections are dated on the profile.